Sildenafil, for the treatment of erectile dysfunction, is one of the first products that has made its way successfully from basic NO (nitrous oxide) research, to clinical routine therapy. Sildenafil , part of the Milestones in Drug Therapy series, presents the major breakthroughs in the field of NO physiology and pharmacology that led to the development of the drug, as well as clinical applications in a one-source guide.

Topical volume about a landmark discovery Written by leading experts in the field Detailed and up-to-date knowledge base Includes supplementary material: sn.pub/extras

Inhalt
The discovery and development of Viagra®(sildenafil citrate).- Sildenafil, pharmacology of a highly selective PDE5 inhibitor.- Sildenafil citrate: a 5-year update on the worldwide treatment of 20 million men with erectile dysfunction.- Current and future strategies for preventing and managing erectile dysfunction following radical prostatectomy.- Neurologic erectile dysfunction.- Therapy of erectile dysfunction (ED) with sildenafil improves quality of life (QoL) and partnership (QoP).- Erectile dysfunction, depression, and pharmacological treatments: biologic interactions.- Potential role for the PDE5 inhibitor sildenafil in the treatment of female sexual dysfunction.- Molecular processing of sildenafil in endothelial function: potential applications in cardiovascular diseases.- Sildenafil and cardiovascular events drug interactions.- Cardiovascular safety of sildenafil in the treatment of erectile dysfunction.- NO pathway and phosphodiesterase inhibitors in pulmonary arterial hypertension.- The phosphodiesterase V inhibitor low responder study (PILRS) in patients with erectile dysfunction A rationale for a PDE5 inhibitor combination therapy.- Extended clinical use of sildenafil in patients with IPP, prostatitis and infertility syndrome.- The cultural impact of sildenafil.